Journal
TRANSPLANTATION PROCEEDINGS
Volume 45, Issue 5, Pages 2040-2044Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.transproceed.2013.01.020
Keywords
-
Categories
Funding
- NCATS NIH HHS [UL1 TR000124] Funding Source: Medline
- NCI NIH HHS [P30 CA016042] Funding Source: Medline
- NCRR NIH HHS [1UL1RR033176, UL1 RR033176] Funding Source: Medline
- NIAID NIH HHS [AI-28697, P30 AI028697, U19 AI 067769, U19 AI067769] Funding Source: Medline
- NIDDK NIH HHS [P30 DK041301] Funding Source: Medline
Ask authors/readers for more resources
We have recently developed a novel and highly efficient strategy that exclusively uses the purine analog 6-thioguanine (6TG) for both pretransplantation conditioning and posttransplantation chemoselection of hypoxanthine-guanine phosphoribosyltransferase (HPRT)-deficient bone marrow (BM). In a mouse BM transplantation model, combined 6TG preconditioning and in vivo chemoselection consistently achieved >95% engraftment of HPRT-deficient donor BM and long-term reconstitution of histologically and immunophenotypically normal hematopoiesis in both primary and secondary recipients, without significant toxicity and in the absence of any other cytotmdc conditioning regimen. To translate this strategy for combined 6TG conditioning and chemoselection into a clinically feasible approach, it is necessary to develop methods for genetic modification of normal hematopoietic stem cells (HSC) to render them HPRT-deficient and thus 6TG-resistant. Here we investigated a strategy to reduce HPRT expression and thereby confer protection against 6TG myelotoxicity to primary murine BM cells by RNA interference (RNAi). Accordingly, we constructed and validated a lentiviral gene transfer vector expressing short-hairpin RNA (shRNA) that targets the murine HPRT gene. Our results showed that lentiviral vector-mediated delivery of HPRT-targeted shRNA could achieve effective and long-term reduction of HPRT expression. Furthermore, in both an established murine cell line as well as in primary murine BM cells, lentiviral transduction with HPRT-targeted shRNA was associated with enhanced resistance to 6TG cytotoxicity in vitro. Hence this represents a translationally feasible method to genetically engineer HSC for implementation of 6TG-mediated preconditioning and in vivo chemoselection.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available